Dose-intensive versus dose-control chemotherapy for high-grade osteosarcoma: a meta-analysis

Area of Science:

• Oncology
• Chemotherapy Research
• Skeletal System Neoplasms

Background:

• Osteosarcoma treatment efficacy may depend on tumor cell sensitivity to chemotherapy dosage, not solely on dose intensity.
• Understanding the role of chemotherapy dosage in osteosarcoma treatment is critical for patient outcomes.

Purpose of the Study:

• To compare the effectiveness of dose-intensive chemotherapy versus dose-controlled chemotherapy for high-grade osteosarcoma.
• To evaluate the impact of different chemotherapy dosing strategies on patient survival and treatment response.

Main Methods:

• A meta-analysis of five studies involving 1434 patients with high-grade osteosarcoma.
• Outcomes analyzed included 5-year disease-free survival, overall survival, local recurrence, histological response, and limb salvage rates.
• Random-effects or fixed-effects models were used based on data heterogeneity.

Main Results:

• No significant differences were observed in 5-year disease-free survival, overall survival, histological response, or limb salvage rates between dose-intensive and dose-controlled groups.
• A significantly lower local recurrence rate was noted in the dose-intensive group (RR: 0.65, 95% CI: 0.46-0.92).
• However, the dose-intensive group showed a significantly higher 5-year disease-free survival rate for patients with good histological response (RR: 1.57, 95% CI: 1.36-1.82).

Conclusions:

• Dose-intensive chemotherapy may not be universally superior for all high-grade osteosarcoma patients.
• Individualized chemotherapy dosage selection is recommended based on clinical case specifics.
• While dose-intensive regimens may offer some benefits, careful consideration of appropriate chemotherapy dosage is essential.